MoonLake Immunotherapeutics Statistics Share Statistics MoonLake Immunotherapeutics has 63.5M
shares outstanding. The number of shares has increased by 0.93%
in one year.
Shares Outstanding 63.5M Shares Change (YoY) 0.93% Shares Change (QoQ) 0.3% Owned by Institutions (%) 93.45% Shares Floating 55.24M Failed to Deliver (FTD) Shares 99 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 5.37M, so 8.45% of the outstanding
shares have been sold short.
Short Interest 5.37M Short % of Shares Out 8.45% Short % of Float 18.96% Short Ratio (days to cover) 13.1
Valuation Ratios The PE ratio is -28.62 and the forward
PE ratio is -14.78.
MoonLake Immunotherapeutics's PEG ratio is
-0.18.
PE Ratio -28.62 Forward PE -14.78 PS Ratio 0 Forward PS n/a PB Ratio 7.62 P/FCF Ratio -29.07 PEG Ratio -0.18
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for MoonLake Immunotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 21.11,
with a Debt / Equity ratio of 0.01.
Current Ratio 21.11 Quick Ratio 21.11 Debt / Equity 0.01 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.19M Employee Count 100 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 282.2K Effective Tax Rate -0.23%
Stock Price Statistics The stock price has increased by 29.16% in the
last 52 weeks. The beta is 1.27, so MoonLake Immunotherapeutics's
price volatility has been higher than the market average.
Beta 1.27 52-Week Price Change 29.16% 50-Day Moving Average 52.79 200-Day Moving Average 46.24 Relative Strength Index (RSI) 68.36 Average Volume (20 Days) 487,609
Income Statement
Revenue n/a Gross Profit -1.38M Operating Income -143.09M Net Income -118.94M EBITDA -119.58M EBIT -120.96M Earnings Per Share (EPS) -1.89
Full Income Statement Balance Sheet The company has 180.43M in cash and 2.83M in
debt, giving a net cash position of 177.6M.
Cash & Cash Equivalents 180.43M Total Debt 2.83M Net Cash 177.6M Retained Earnings -235.59M Total Assets 460.1M Working Capital 428.12M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -116.59M
and capital expenditures -519.52K, giving a free cash flow of -117.11M.
Operating Cash Flow -116.59M Capital Expenditures -519.52K Free Cash Flow -117.11M FCF Per Share -1.86
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
